MetaCap

Replimune Group (REPL) vs Recursion Pharmaceuticals (RXRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Replimune Group (REPL) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, gaining 107.3% versus a loss of 41.2%. Over five years, REPL leads with a -34.2% price change compared with -87.0% for RXRX. Replimune Group is the larger company by market cap ($1.81 billion vs $1.53 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

REPL+107.28%RXRX-41.25%
+165%+36%-93%
Nov 21, 20251 yearNov 20, 2026
REPL-44.32%RXRX-87.63%
+5%-47%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

REPL versus RXRX key metrics
MetricREPLRXRX
Share price$19.07$2.45
Market cap$1.81B$1.53B
1-day change-0.83%-9.93%
YTD return+96.19%-40.10%
1-year return+107.28%-41.25%
5-year return-34.24%-87.04%
EPS (TTM)$-2.79$-0.86
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$74.68M
Revenue growth (YoY)—+26.92%
Net income (latest FY)$-313.94M$-644.76M
Gross margin—4.99%
Operating margin—-867.87%
Net margin—-863.35%
52-week high$23.54$5.24
52-week low$1.50$2.44
Distance from 52-week high-18.99%-53.24%
Analyst consensusbuybuy
Avg. price target upside+33.72%+176.33%
Average volume2.48M24.47M
Shares outstanding94.80M622.76M
Employees465600
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • REPL has outperformed RXRX by 148.5 percentage points over the past year.

About Replimune Group

REPL stock →

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 465 employees

About Recursion Pharmaceuticals

RXRX stock →

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees

REPL vs RXRX FAQ

Which is bigger, Replimune Group or Recursion Pharmaceuticals?

Replimune Group (REPL) is larger, with a market capitalization of $1.81B compared with $1.53B for Recursion Pharmaceuticals (RXRX).

Which stock has performed better over the past year, REPL or RXRX?

REPL returned +107.28% over the past 12 months, compared with -41.25% for RXRX (price return, excluding dividends). Past performance does not predict future results.

Are Replimune Group and Recursion Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons